Athersys, Inc ATHX
We take great care to ensure that the data presented and summarized in this overview for ATHERSYS, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ATHX
Top Purchases
Top Sells
About ATHX
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Insider Transactions at ATHX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2023
|
Maia Hansen COO |
SELL
Payment of exercise price or tax liability
|
Direct |
67
-0.1%
|
$0
$0.02 P/Share
|
|
Oct 04
2023
|
Maia Hansen COO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,149
-24.81%
|
$0
$0.44 P/Share
|
|
Oct 04
2023
|
Daniel A. Camardo CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,993
-6.55%
|
$0
$0.44 P/Share
|
|
Sep 18
2023
|
Maia Hansen COO |
SELL
Payment of exercise price or tax liability
|
Direct |
67
-0.09%
|
$0
$0.3 P/Share
|
|
Jul 05
2023
|
Maia Hansen COO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,026
-8.34%
|
$0
$0.91 P/Share
|
|
Jul 05
2023
|
Daniel A. Camardo CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,993
-6.15%
|
$0
$0.91 P/Share
|
|
Jun 16
2023
|
Maia Hansen COO |
SELL
Payment of exercise price or tax liability
|
Direct |
270
-0.32%
|
$0
$0.93 P/Share
|
|
Apr 04
2023
|
Daniel A. Camardo CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,993
-5.79%
|
$19,993
$1.0 P/Share
|
|
Apr 04
2023
|
Maia Hansen COO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,366
-8.02%
|
$7,366
$1.0 P/Share
|
|
Jan 09
2023
|
Jane Wasman Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,321
+38.84%
|
-
|
|
Jan 09
2023
|
Ismail Kola Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,714
+37.23%
|
-
|
|
Jan 09
2023
|
Joseph Patrick Nolan Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,951
+50.0%
|
-
|
|
Jan 09
2023
|
Jack L Wyszomierski Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,321
+38.84%
|
-
|
|
Jan 04
2023
|
Maia Hansen COO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,253
-8.24%
|
$0
$0.85 P/Share
|
|
Jan 04
2023
|
Daniel A. Camardo CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,484
-6.37%
|
$0
$0.85 P/Share
|
|
Dec 19
2022
|
Maia Hansen COO |
SELL
Payment of exercise price or tax liability
|
Direct |
67
-0.88%
|
$0
$0.81 P/Share
|
|
Nov 22
2022
|
Daniel A. Camardo CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+21.33%
|
$0
$0.55 P/Share
|
|
Oct 04
2022
|
Daniel A. Camardo CEO |
BUY
Grant, award, or other acquisition
|
Direct |
263,492
+49.5%
|
-
|
|
Oct 04
2022
|
Maia Hansen COO |
BUY
Grant, award, or other acquisition
|
Direct |
92,593
+48.02%
|
-
|
|
Sep 19
2022
|
Maia Hansen COO |
SELL
Payment of exercise price or tax liability
|
Direct |
12
-0.16%
|
$12
$1.61 P/Share
|